NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo
Kenji Namoto(Novartis (Switzerland)), Michael T. Dill(German Cancer Research Center), Clemens Scheufler(Novartis (Switzerland)), Felix Lohmann(Pathways Behavioral Services), Linda E. Greenbaum(Novartis (United States)), Louis Wang(Tris Pharma (United States)), Bindi Sohal(Novartis (Switzerland)), Olivera Evrova(ETH Zurich), Eva Breuer(University Hospital of Zurich), Wei‐Yu Lu(MRC Centre for Regenerative Medicine), Ralf Glatthar(Novartis (Switzerland)), Rosemarie Ungricht(Novartis (Switzerland)), Magali Ferro(Novartis (Switzerland)), Philipp S. Hoppe(Novartis (Switzerland)), Alexandro Landshammer(Max Planck Institute for Molecular Genetics), Monika Pikiolek(Novartis (Switzerland)), Katharina Schönberger(University of Freiburg), Alexandra Aebi(Novartis (Switzerland)), Bo Lü(Chinese Academy of Medical Sciences & Peking Union Medical College), Armin Beyerbach(Novartis (Switzerland)), Tianliang Sun(Institute for Stem Cell Biology and Regenerative Medicine), Bostjan Humar(University Hospital of Zurich), Paola Capodieci(Pathways Behavioral Services), Eric Vangrevelinghe(Novartis (Switzerland)), Feng Cong(Guangdong Laboratory Animals Monitoring Institute), Andreas W. Sailer(Novartis (Switzerland)), Vincent Unterreiner(Novartis (Switzerland)), Stuart J. Forbes(MRC Centre for Regenerative Medicine), Julie Lachal(Novartis (Switzerland)), Christian N. Parker(Novartis (Switzerland)), Sukhdeep Sahambi(Tris Pharma (United States)), Armelle Grevot(Novartis (Switzerland)), Tewis Bouwmeester(Institute of Pathology Celle), Pierre‐Alain Clavien(University Hospital of Zurich), Gabi Schutzius(Novartis (Switzerland)), Markus Trunzer(Novartis (Switzerland)), Vanessa Orsini(Novartis (Switzerland)), Heinz Ruffner(Novartis (Switzerland)), Stefano Annunziato(Novartis (Switzerland)), Emily Redmond(Tris Pharma (United States)), Jun Liu(Sichuan University), Stéphane Laurent(Novartis (Switzerland)), Nicole Buschmann(Novartis (Switzerland)), Jürgen Wagner(Vogtland-Klinik), Kristie Wetzel(Novartis (Switzerland)), Clara Baader(University of Basel), Kieu Trinh Dinh(German Cancer Research Center), Rainer Machauer(Novartis (Switzerland)), Dirk Behnke(Novartis (Switzerland)), Jonathan Turner(Novartis (Switzerland))
Cited by 36
Related Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Nuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration
|Science|2006|635
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers
|Journal of Medical Genetics|2015|567
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
|Cell Reports|2018|526